MYOV News and Press, Myovant Sciences Ltd. From 10/25/21

AAN,ABG,ADM,ARCC,ARCH,AUDC,BDN,CAJ,CEQP,CIT,CLS,CNC,CVLT,CZOO,DAN,ECL,ENTG,GBX,GE,GLW,GPK,HAS,HUBB,OTCPK:HYMLF,HZO,INMD,IVZ,JBLU,LLY,LMT,MMM,MMYT,MSCI,MYOV,OTCQX:NHYDY,NVS,ORAN,OXSQ,PCAR,PERI,PHM,PII,PJT,PNR,RTX,SHW,SPGI,SSTK,ST,TPB,TRTN,TRU,UBS,UPS,WM,XRX For Seeking Alpha's full earnings se...

BASEL, Switzerland and NEW YORK, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced the presentation of new data from clinical studies of its once-daily relugolix combination therapy (relugolix 40 mg plus estradiol 1.0 mg and nor...

BASEL, Switzerland, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced it will host a webcast and conference call to discuss corporate updates and financial results for its second fisca...

RETHYMIC is the first and only FDA-approved treatment indicated for immune reconstitution in pediatric patients with congenital athymia Children with congenital athymia are born without a thymus causing severe immunodeficiency and immune dysregulation - with only supportive care t...

Filing in endometriosis is supported by data from the Phase 3 SPIRIT program FDA PDUFA target action date is May 6, 2022 BASEL, Switzerland and NEW YORK, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced tha...

BASEL, Switzerland, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, will participate in the 2021 Baird Global Healthcare Conference on September 15, 2021. Company management will participate in a f...

On average, pediatric congenital athymia patients spent 150.6 days each year in the hospital with a mean total cost of $5,534,121 for supportive care over three years Mean total costs for patients with annual inpatient stays of 365 days are $11,763,320 over three years W...

BASEL, Switzerland, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and men, today announced the appointment of Uneek Mehra as Chief Financial and Business Officer of Myovant Sciences, Inc.  Mr. Mehra will succe...

Kaplan-Meier estimated survival at one year and two years post treatment with investigational RVT-802 was 77% and 76%, respectively Follow-up time in the Efficacy Analysis Set (EAS) ranged from 0 to 25.5 years; For patients who were alive at one year post treatment, the Kaplan-M...

Image source: The Motley Fool. Myovant Sciences Ltd. (NYSE: MYOV) Q1 2021 Earnings Call Jul 28, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: Myovant Sciences Ltd. (MYOV) Q1 2021 Earnings Call Transcript